Exhibit 12.1
OncoGenex Pharmaceuticals, Inc.
Statement of Computation of Ratio of Earnings to Fixed Charges
Fiscal Year Ended December 31, | Nine Months Ended September 30, 2012 | |||||||||||||||||||||||
(In $000’s, except ratio) | 2007 | 2008 | 2009 | 2010 | 2011 | |||||||||||||||||||
Fixed Charges: | ||||||||||||||||||||||||
Interest expense | $ | 193 | $ | 749 | $ | 1,251 | $ | 1,172 | $ | 1,086 | $ | 744 | ||||||||||||
Amortized premiums, discounts and capitalized expenses related to indebtedness | 2,944 | 1,973 | — | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
| $ | 3,137 | $ | 2,722 | $ | 1,251 | $ | 1,172 | $ | 1,086 | $ | 744 | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Earnings (loss): | ||||||||||||||||||||||||
Net loss before income tax benefit (provision) | $ | (7,823 | ) | $ | (10,691 | ) | $ | (2,465 | ) | $ | (15,584 | ) | $ | (14,673 | ) | $ | (16,995 | ) | ||||||
Add fixed charges | 3,137 | 2,722 | 1,251 | 1,172 | 1,086 | 744 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
| $ | (4,686 | ) | $ | (7,969 | ) | $ | (1,214 | ) | $ | (14,412 | ) | $ | (13,587 | ) | $ | (16,251 | ) | |||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Ratio of earnings to fixed charges | — | — | — | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Deficiency of earnings to fixed charges | $ | (7,823 | ) | $ | (10,691 | ) | $ | (2,465 | ) | $ | (15,584 | ) | $ | (14,673 | ) | $ | (16,995 | ) | ||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
